Sign in
Taking people in United StatesEarly phase 1

Tests CBL0137 with ipilimumab and nivolumab in advanced melanoma

Tests a new drug, CBL0137, with two immunotherapy drugs in adults with melanoma.

Key facts

Who runs it
Fox Chase Cancer Center
Where
Philadelphia, United StatesSee the site
Trial code
Registry title
Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma
Status
Recruiting
Phase
Early phase 1
People taking part
12 people, planned
Started
30 Nov 2022
Expected to end
2 Sept 2027
Type of study
Interventional, 3 groups
Treatments tested
  • CBL0137
  • Ipilimumab
  • Nivolumab
Record updated
22 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with melanoma that has spread to nearby lymph nodes or elsewhere in the body and can be biopsied repeatedly. It tests CBL0137 together with ipilimumab and nivolumab.

Age
Over 18 years
Sex
All sexes
Disease stage
Stage III melanoma with one or more lymph node metastases that can be biopsied or operated on, or stage III or stage IV disease that can be biopsied repeatedly, as judged by the treating doctor.
Earlier treatment
People who had earlier treatment targeting the CTLA-4 or PD1/PD-L1 pathway cannot join.

Main reasons for not taking part

  • Taking any other investigational agent
  • Known active autoimmune disease
  • Earlier treatment targeting the CTLA-4 or PD1/PD-L1 pathway
  • Another condition needing immunosuppressive medicine or high-dose steroids
  • Ongoing diarrhea (more than 4 bowel movements a day) despite care in the 2 weeks before treatment

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Patients must have:; Pathologically proven stage III melanoma with one or more macroscopic lymph node metastases (measurable according to RECIST v. 1.1) amenable to biopsy and/or surgery OR:; Patients considered to have stage III or stage IV disease amenable to serial biopsies as determined by the treating physician. Note: patients with in-transit metastasis may be eligible after surgical consultation if not surgical candidates; Patients must have disease amenable to and must be willing to undergo protocol-directed repeat biopsies and blood draws
  • Age > 18 years
  • ECOG performance status 0 or 1
  • Patients must have normal organ and marrow function

Who cannot take part

  • Patients may not be receiving any other investigational agents
  • Prior treatment with CTLA-4 or PD1/PD-L1 pathway targeted systemic treatment
  • Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic corticosteroids
  • Patients with ongoing diarrhea (> 4 bowel movements/day) unresolved despite medical and best supportive care in the two weeks preceding therapy
  • Patients with a known active autoimmune disease

Where in United States

  • Fox Chase Cancer CenterPhiladelphia, United StatesContact: Anthony J. OlszanskiTaking people

About the trial

What the trial wants to find out

Phase I, open label, dose-escalation, and safety study designed to assess the safety and biologic activity of the investigational agent CBL0137 in combination with standard of care drugs, ipilimumab and nivolumab in sequential cohorts of adult patients with locally advanced and metastatic melanoma who are candidates for immune checkpoint blockade and have tumors accessible for serial biopsies.

The 3 groups in the trial

  • CBL0137 (Dose level 1) +Ipilimumab + NivolumabTreatment being tested

    Dose level 1 CBL0137 on Days 1 and 8, Nivolumab and Ipilimumab on days 8 and 29 administrated IV of 8 weeks treatment cycles.

    Treatment: CBL0137, Ipilimumab, and Nivolumab

  • CBL0137 ( Dose level 2) +Ipilimumab + NivolumabTreatment being tested

    Dose level 2 CBL0137 on Days 1 and 8, Nivolumab and Ipilimumab on days 8 and 29 administrated IV of 8 weeks treatment cycles.

    Treatment: CBL0137, Ipilimumab, and Nivolumab

  • CBL0137 ( Dose level -1) +Ipilimumab + NivolumabTreatment being tested

    Dose level -1 CBL0137 on Days 1 and 8, Nivolumab and Ipilimumab on days 8 and 29 administrated IV of 8 weeks treatment cycles.

    Treatment: CBL0137, Ipilimumab, and Nivolumab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
MEL-212: A Phase I Proof-of-Concept Study of CBL0137 (Curaxin) Combined With Ipilimumab and Nivolumab Therapy in Locally Advanced or Metastatic Melanoma
Plain-language title
Tests CBL0137 with ipilimumab and nivolumab in advanced melanomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
22 May 2026